RxDoctor Payments DataLook up a doctor →

Joseph Acosta, MD

Neurology · Baton Rouge, LANPI 1710976915

Payments from drug & device makers

$32,827in general payments, 2019–2025

Across 1,894 payments — averaging $17.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Teva Pharmaceuticals USA, Inc.$3K
  • UCB, Inc.$2K
  • Acadia Pharmaceuticals Inc$2K
  • Amgen$1K
  • Pfizer$1K
  • plus $19K from 54 others

What the payments were for

  • Speaking & faculty fees$1991%
  • Travel & lodging$2201%
  • Food & beverage$32,12498%
  • Education$2851%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)329$4,246
Teva Pharmaceuticals USA, Inc.127$2,650
UCB, Inc.101$1,948
Acadia Pharmaceuticals Inc96$1,667
Amgen(2 entities)84$1,493
Pfizer111$1,411
Lundbeck LLC66$1,208
Sunovion Pharmaceuticals Inc.76$1,200
Sanofi55$1,131
Novartis57$1,125
Biogen52$904
Lilly USA, LLC51$836
Grifols USA, LLC37$807
Argenx US, Inc.32$714
EMD Serono, Inc.34$663
Medtronic9$614
SK Life Science, Inc.27$610
Eisai Inc.33$601
Neurelis, Inc.27$591
Amneal Pharmaceuticals LLC30$472
Biohaven Pharmaceutical Holding Company Ltd.38$455
Kyowa Kirin, Inc.24$451
Supernus Pharmaceuticals, Inc.32$430
AstraZeneca(2 entities)22$425
Takeda Pharmaceuticals U.S.A., Inc.15$360
Otsuka America Pharmaceutical, Inc.26$356
Jazz Pharmaceuticals Inc.18$356
Tanabe Pharma America, Inc.20$354
Johnson & Johnson(2 entities)21$344
CSL Behring15$312
Ipsen Biopharmaceuticals, Inc15$306
Avanir Pharmaceuticals, Inc.18$297
MDD US Operations, LLC16$278
GE HealthCare13$272
Acorda Therapeutics, Inc12$236
Bristol Myers Squibb11$214
Kedrion Biopharma Inc.10$213
Neurocrine Biosciences, Inc.10$206
Biohaven Pharmaceuticals, Inc.18$203
Upsher-smith Laboratories LLC11$201
ANI Pharmaceuticals, Inc.8$170
Scilex Pharmaceuticals Inc.8$145
Genentech USA, Inc.8$118
Sumitomo Pharma America, Inc.11$110
Merz Pharmaceuticals, LLC4$94
Zyla Life Sciences, Inc.5$93
Zogenix Inc.4$76
Alnylam Pharmaceuticals Inc.3$71
Piramal Critical Care4$58
Boston Scientific2$46
Assertio Therapeutics, Inc.3$40
Arbor Pharmaceuticals, Inc.3$39
Vanda Pharmaceuticals Inc.1$38
Sarepta Therapeutics, Inc.2$36
Akcea Therapeutics, Inc.1$35
Mallinckrodt Enterprises LLC2$35
Adamas Pharmaceuticals, Inc.2$35
Impel Pharmaceuticals Inc.2$33
E.r. Squibb & Sons, L.L.C.2$32
Axsome Therapeutics, Inc.2$31

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$32,827 in reported general payments places this provider in the 85th percentile of 225 neurology providers in Louisiana.

See all neurology providers in Louisiana

Medicare billing

Part B allowed, 2024
$147,607
Medicare patients
434
Services billed
4,848

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OctagamImmun Globg(Igg)/Malt/Iga Ov5056$1,014,017
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5042$672,864
GammakedImmune Globul G/Gly/Iga Avg 4626$451,505
Gamunex-CImmune Globul G/Gly/Iga Avg 4660$364,996
NuplazidPimavanserin Tartrate55$197,619
AustedoDeutetrabenazine31$176,389
PanzygaImmun Glob G(Igg)-Ifas/Glycine15$176,101
Rebif RebidoseInterferon Beta-1a/Albumin12$119,587
RexultiBrexpiprazole29$38,167
AptiomEslicarbazepine Acetate19$26,673
FycompaPerampanel22$25,809
Nurtec OdtRimegepant Sulfate20$20,376
QuliptaAtogepant19$20,042
XcopriCenobamate15$18,101
Aimovig AutoinjectorErenumab-Aooe19$17,239

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerOctagam, Panzyga, Nurtec Odt, Eliquis$1,411$1,221,678106 claims
CSL BehringPrivigen$312$672,86442 claims
Grifols USA, LLCGamunex-C$807$364,99660 claims
Acadia Pharmaceuticals IncNuplazid$1,667$197,61955 claims
Teva Pharmaceuticals USA, Inc.Austedo$2,650$176,38931 claims
Otsuka America Pharmaceutical, Inc.Rexulti$356$38,16729 claims
AbbVieQulipta, Ubrelvy$4,246$34,45036 claims
Sunovion Pharmaceuticals Inc.Aptiom$1,200$26,67319 claims
Eisai Inc.Fycompa$601$25,80922 claims
SK Life Science, Inc.Xcopri$610$18,10115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 225 neurology providers in Louisiana.

Other neurology in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →